Few application reviews in recent years have generated as much public attention as Sarepta Therapeutics Inc.'s eteplirsen, especially remarkable because of the product is seeking approval for an orphan disease, Duchenne muscular dystrophy (DMD). FDA's release of tangential guidance caused stock gyrations, and agency silence on the review has prompted an angry Wall Street Journal editorial.
For FDA tea-leaf readers, though, the agency's recent actions on another DMD application may offer a further sense of how...






